Piqray plus Faslodex significantly improved PFS in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast ...

The 36-month PFS rate for patients with del (17p) and/or TP53 mutation was 87% and for patients without del (17p) and TP53 mutation was 89%. The safety profile of BRUKINSA plus venetoclax was ...

Topline data were announced from a phase 3 trial evaluating varegacestat in patients with progressing desmoid tumors.

Over the past six months, Provident Financial Services has been a great trade, beating the S&P 500 by 6.6%. Its stock price ...

Final results from the phase 3 CASSANDRA trial presented at the 2025 ASCO Meeting show that the neoadjuvant chemotherapy ...

The Personal Financial Specialist (PFS) certification helps Certified Public Accountants (CPAs) demonstrate an expertise in all aspects of wealth management. A PFS is someone with a CPA who also ...

Varegacestat, an investigational gamma secretase inhibitor (GSI), delivered clinically meaningful improvements in efficacy outcomes vs placebo in patients with progressing desmoid tumors, according to ...

The optimal approach to treatment in the post-CDK4/6 inhibitor setting remains undefined, but multiple strategies have ...

Although frontline maintenance treatment with fuzuloparib monotherapy produced a progression-free survival (PFS) benefit in patients with newly diagnosed advanced ovarian cancer, the addition of ...